FF 86 Atacicept for IgAN with Jon Barratt

The Filtrate

Joel Topf‍ ‍@kidneyboy.bsky.social‬ (COI)

Sophia Ambruso @sophia-kidney.bsky.social

Swapnil Hiremath @hswapnil.medsky.social and on LinkedIn

Special Guests

Jonathan Barratt Professor of Renal Medicine, University of Leicester Google Scholar (COI: all the companies)

Editing and Show Notes by

Nayan Arora @captainchloride.bsky.social

The Kidney Connection written and performed by Tim Yau

Show Notes

Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy (Aliza Thompson, 2019 PubMed)

The number, quality, and coverage of randomized controlled trials in nephrology (PubMed 2004)

Updated here (PubMed | NephJC discussion)

A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction (PubMed 2017)

BLISS Belimumab in lupus nephritis (NephJC | PubMed)

The Phase 2 trial of atacicept A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy (PubMed)

The phase 3 trial of atacicept, the subject of this podcast A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy (PubMed | NephJC)

Christos’ Bluesky post:

https://bsky.app/profile/christosargyrop.bsky.social/post/3m5bsujwg3s2q

The use of Gd-IgA1 in the Testing Trial Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy (PubMed)

If you can’t get enough Jon Barratt, take a look at his grand rounds at The University of Ottawa. Updates to the KDIGO Guidelines for the treatment of IgA nephropathy, with Prof Jonathan Barratt (YouTube)

Tubular Secretion

Swapnil Hiremath Pluribus on Apple TV (.css-j9qmi7{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;font-weight:700;margin-bottom:1rem;margin-top:2.8rem;width:100%;-webkit-box-pack:start;-ms-flex-pack:start;-webkit-justify-content:start;justify-content:start;padding-left:5rem;}@media only screen and (max-width: 599px){.css-j9qmi7{padding-left:0;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;}}.css-j9qmi7 svg{fill:#27292D;}.css-j9qmi7 .eagfbvw0{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;color:#27292D;}